These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

645 related articles for article (PubMed ID: 36829496)

  • 1. Targets of Immune Escape Mechanisms in Cancer: Basis for Development and Evolution of Cancer Immune Checkpoint Inhibitors.
    Dutta S; Ganguly A; Chatterjee K; Spada S; Mukherjee S
    Biology (Basel); 2023 Jan; 12(2):. PubMed ID: 36829496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting Checkpoint Receptors and Molecules for Therapeutic Modulation of Natural Killer Cells.
    Kim N; Kim HS
    Front Immunol; 2018; 9():2041. PubMed ID: 30250471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NK Cell-Based Immune Checkpoint Inhibition.
    Khan M; Arooj S; Wang H
    Front Immunol; 2020; 11():167. PubMed ID: 32117298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Manipulation of the Immune System for Cancer Defeat: A Focus on the T Cell Inhibitory Checkpoint Molecules.
    D'Arrigo P; Tufano M; Rea A; Vigorito V; Novizio N; Russo S; Romano MF; Romano S
    Curr Med Chem; 2020; 27(15):2402-2448. PubMed ID: 30398102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging targets in cancer immunotherapy.
    Burugu S; Dancsok AR; Nielsen TO
    Semin Cancer Biol; 2018 Oct; 52(Pt 2):39-52. PubMed ID: 28987965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combinatorial blockade for cancer immunotherapy: targeting emerging immune checkpoint receptors.
    Roy D; Gilmour C; Patnaik S; Wang LL
    Front Immunol; 2023; 14():1264327. PubMed ID: 37928556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NKG2A Immune Checkpoint in Vδ2 T Cells: Emerging Application in Cancer Immunotherapy.
    Cazzetta V; Depierreux D; Colucci F; Mikulak J; Mavilio D
    Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
    Xia L; Liu Y; Wang Y
    Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune checkpoint inhibitor combinations: Current efforts and important aspects for success.
    Kon E; Benhar I
    Drug Resist Updat; 2019 Jul; 45():13-29. PubMed ID: 31382144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Leveraging NKG2D Ligands in Immuno-Oncology.
    Fuertes MB; Domaica CI; Zwirner NW
    Front Immunol; 2021; 12():713158. PubMed ID: 34394116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune Checkpoint Inhibitors in Colorectal Cancer: Challenges and Future Prospects.
    Makaremi S; Asadzadeh Z; Hemmat N; Baghbanzadeh A; Sgambato A; Ghorbaninezhad F; Safarpour H; Argentiero A; Brunetti O; Bernardini R; Silvestris N; Baradaran B
    Biomedicines; 2021 Aug; 9(9):. PubMed ID: 34572263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4.
    Qin S; Xu L; Yi M; Yu S; Wu K; Luo S
    Mol Cancer; 2019 Nov; 18(1):155. PubMed ID: 31690319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune checkpoint inhibitors in cancer therapy: a focus on T-regulatory cells.
    Sasidharan Nair V; Elkord E
    Immunol Cell Biol; 2018 Jan; 96(1):21-33. PubMed ID: 29359507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Insights Into Novel Immune Checkpoint Inhibitors.
    Lee JB; Ha SJ; Kim HR
    Front Pharmacol; 2021; 12():681320. PubMed ID: 34025438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Use of Immune Checkpoint Inhibitors in Oncology and the Occurrence of AKI: Where Do We Stand?
    Franzin R; Netti GS; Spadaccino F; Porta C; Gesualdo L; Stallone G; Castellano G; Ranieri E
    Front Immunol; 2020; 11():574271. PubMed ID: 33162990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitory Receptors and Immune Checkpoints Regulating Natural Killer Cell Responses to Cancer.
    Buckle I; Guillerey C
    Cancers (Basel); 2021 Aug; 13(17):. PubMed ID: 34503073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune checkpoints and cancer development: Therapeutic implications and future directions.
    Mehdizadeh S; Bayatipoor H; Pashangzadeh S; Jafarpour R; Shojaei Z; Motallebnezhad M
    Pathol Res Pract; 2021 Jul; 223():153485. PubMed ID: 34022684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting NK Cell Checkpoint Receptors or Molecules for Cancer Immunotherapy.
    Zhang C; Liu Y
    Front Immunol; 2020; 11():1295. PubMed ID: 32714324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD/1-PD-Ls Checkpoint: Insight on the Potential Role of NK Cells.
    Pesce S; Greppi M; Grossi F; Del Zotto G; Moretta L; Sivori S; Genova C; Marcenaro E
    Front Immunol; 2019; 10():1242. PubMed ID: 31214193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beyond CTLA-4 and PD-1 Inhibition: Novel Immune Checkpoint Molecules for Melanoma Treatment.
    Ziogas DC; Theocharopoulos C; Lialios PP; Foteinou D; Koumprentziotis IA; Xynos G; Gogas H
    Cancers (Basel); 2023 May; 15(10):. PubMed ID: 37345056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.